We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Starting Oct. 1, pharma companies seeking to cash in on a rare pediatric disease priority review voucher must pay the FDA $2.727 million — $165,000 more than in the fiscal year ending Wednesday. Read More
An interim report shows that the FDA has conducted nearly 90 meetings with more than 50 drug companies interested in producing biosimilar products since 2013 at a cost of $65.9 million. Read More
Bausch & Lomb and Nicox are calling their once-daily eye drop for treating both open angle glaucoma and ocular hypertension a milestone in research and development in a medical area that has seen few new treatments in recent years. Read More
Swiss health authority Swissmedic has approved Novartis’ Entresto, enabling other health authorities to complete their reviews of the heart failure drug. Read More